GlassScriptPhysician profile
Suresh K Misra
NPI 1174588768
$15,718.95
in general payments reported to CMS, 2019-2025
45 companies · $2,592 in 2025
The $2,592 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,697 · 2020: $1,231 · 2021: $2,378 · 2022: $1,199 · 2023: $2,626 · 2024: $1,997 · 2025: $2,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,176 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,175.52 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,825.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,448.77 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $976.79 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $951.02 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $788.94 | 2019-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $671.16 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $596.73 | 2019-2024 | |
| Abbvie INC. | $545.60 | 2021-2025 | |
| Novo Nordisk INC | $498.60 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $486.53 | 2020-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $472.04 | 2020-2025 | Jardiance, Mounjaro, Trulicity |
| Nestle Healthcare Nutrition INC. | $376.01 | 2023 | |
| Daiichi Sankyo INC. | $373.54 | 2021-2023 | Injectafer |
| Astellas Pharma US INC | $357.23 | 2020-2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $354.20 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.